Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS)

摘要

Frequency of cardiac disorders in the FDA Adverse Event Reporting System 2015 Q1 to 2020 Q1. a Demonstrates the proportion of cardiac disorders among individuals without coronavirus indications. b Demonstrates the proportion of cardiac disorders among individuals with coronavirus indications. AEs adverse events, CQ chloroquine, HCQ hydroxychloroquine, Sulbacta sulbactam, Tazo tazobactam